替吉奥联合多西他赛对晚期胃癌患者血清肿瘤标志物水平的影响及安全性分析  

Effect and safety analysis of tegafur,gimeracil and oteracil porassium capsules combined with docetaxel on serum tumor markers in patients with advanced gastric cancer

作　　者：刘彪 张翼 吴敏娟 诸葛群 LIU Biao;ZHANG Yi;WU Minjuan;ZHUGE Qun(Department of Gastroenterology,Shangrao People's Hospital,Shangrao,Jiangxi,334000,China)

机构地区：[1]上饶市人民医院消化内科,江西上饶334000

出　　处：《当代医学》2023年第24期45-48,共4页Contemporary Medicine

摘　　要：目的探讨替吉奥联合多西他赛对晚期胃癌患者血清神经元特异性烯醇化酶(NSE)、癌胚抗原125(CA125)、重组人S100钙结合蛋白A4(S100A4)水平的影响及安全性。方法选取2018年1月至2021年1月本院收治的68例晚期胃癌患者作为研究对象,按照简单随机抽样方法分为对照组与观察组,各34例。对照组采用多西他赛治疗,观察组在对照组基础上联合替吉奥胶囊治疗,比较两组临床疗效、生命质量和血清NSE、CA125、S100A4水平及治疗期间不良反应发生情况。结果观察组治疗后总缓解率为67.65%,高于对照组的41.18%,差异有统计学意义(P<0.05)。两组生命质量评分组间、时间、交互比较差异有统计学意义(P<0.05)。组内比较:两组治疗后各时间点生命质量评分均高于前一时间点,差异有统计学意义(P<0.05)。组间比较:治疗前,两组生命质量评分比较差异无统计学意义;治疗1、2、3个月后,观察组生命质量评分均高于对照组,差异有统计学意义(P<0.05)。治疗后,两组血清NSE、CA125、S100A4水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。观察组不良反应总发生率为17.65%,明显低于对照组的41.18%,差异有统计学意义(P<0.05)。结论替吉奥联合多西他赛可有效降低晚期胃癌患者血清NSE、CA125、S100A4水平,提高临床疗效及患者生命质量,降低不良反应发生率,安全性较高,值得临床推广应用。Objective To investigate the effects and safety of tegafur,gimeracil and oteracil porassium capsules combined with docetaxel on serum levels of neuron-specific enolase(NSE),carcinoembryonic antigen 125(CA125)and recombinant human S100 calcium-binding protein A4(S100A4)in patients with advanced gastric cancer.Methods 68 patients with advanced gastric cancer admitted to our hospital from January 2018 to January 2021 were selected as the research subject,and they were divided into the control group and the observation group according to simple random sampling method,with 34 cases in each group.The control group was treated with docetaxel,and the observation group was treated with tegafur,gimeracil and oteracil porassium capsules on the basis of the control group,the clinical efficacy,quality of life and serum NSE,CA125,S100A4 levels and adverse reactions during the treatment were compared between the two groups.Results The total remission rate in the observation group was 67.65%,which was higher than 41.18%in the control group,and the difference was statistically significant(P<0.05).There were significant differences in the quality between the two groups of groups,time points and interaction(P<0.05).Comparison within group:the quality of life score of the two groups at each time point after treatment were higher than that of the previous time point,and the differences were statistically significant(P<0.05).Comparison between groups:before treatment,there was no significant difference in quality of life score between the two groups;after 1,2,3 months of treatment,the quality of life scores in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of serum NSE,CA125 and S100A4 in the two groups were lower than those before treatment,and the observation group was lower than that the control group,and the differences were statistically significant(P<0.05).During the treatment,the total incidence of adverse reactions in the o

关 键 词：胃癌 晚期 替吉奥 多西他赛 神经元特异性烯醇化酶 癌胚抗原125 重组人S100钙结合蛋白A4 

分 类 号：R735.2[医药卫生—肿瘤]